Objective-Genome-wide association studies have identified several genetic variants associated with coronary heart disease (CHD). The aim of this study was to evaluate the genetic risk discrimination and reclassification and apply the results for a 2-stage population risk screening strategy for CHD. Approach and Results-We genotyped 28 genetic variants in 24 124 participants in 4 Finnish population-based, prospective cohorts (recruitment years 1992-2002). We constructed a multilocus genetic risk score and evaluated its association with incident cardiovascular disease events. During the median follow-up time of 12 years (interquartile range 8.75-15.25 years), we observed 1093 CHD, 1552 cardiovascular disease, and 731 acute coronary syndrome events. Adding genetic information to conventional risk factors and family history improved risk discrimination of CHD (C-index 0.856 versus 0.851; P=0.0002) and other end points (cardiovascular disease: C-index 0.840 versus 0.837, P=0.0004; acute coronary syndrome: C-index 0.859 versus 0.855, P=0.001). In a standard population of 100 000 individuals, additional genetic screening of subjects at intermediate risk for CHD would reclassify 2144 subjects (12%) into high-risk category. Statin allocation for these subjects is estimated to prevent 135 CHD cases over 14 years. Similar results were obtained by external validation, where the effects were estimated from a training data set and applied for a test data set. Conclusions-Genetic risk score improves risk prediction of CHD and helps to identify individuals at high risk for the first CHD event. Genetic screening for individuals at intermediate cardiovascular risk could help to prevent future cases through better targeting of statins. (Arterioscler Thromb Vasc Biol. 2013;33:2261-2266.)
C oronary heart disease (CHD) is a complex disorder with the risk modified by both environmental and genetic factors. At present, the established risk factors, such as high cholesterol and blood pressure, explain only a fraction of the variability in disease risk. This has motivated a search for new predictors, including genetic markers. Several genome-wide association studies have identified many novel genetic susceptibility loci for CHD. [1] [2] [3] Although causal variants and biological function are still unknown for many of the loci, their potential for better identifying the high-risk individuals has been studied. Genetic risk scores (GRSs) based on the subsets of the most strongly associated single-nucleotide polymorphisms (SNPs) in the identified loci have been associated with future CHD events in samples of European origin, [4] [5] [6] [7] but studies so far have shown little or no additional value for GRS' ability to predict future cases of CHD over the traditional risk factors.
See accompanying article on page 2049
Recently, the Emerging Risk Factors Collaboration 8, 9 has evaluated lipid-related and inflammatory markers by their ability to improve risk classification in a 2-stage population screening strategy. In this approach, a population of 100 000 individuals is first screened for the traditional cardiovascular risk factors. In the second stage, additional screening based on a novel risk marker is conducted for the subjects at the intermediate-risk category (10- year risk, 10%-20%). The guidelines from National Institute for Health and Care Excellence 10 and ATP-III 11 among others recommend that statin treatment should be allocated for the individuals with 10-year absolute risk of cardiovascular disease (CVD) >20%. Thus, identification of individuals at the intermediate-risk category, who would benefit from long term statin medication, could have both clinical and population health benefits.
In this study, we genotyped 28 previously identified genetic risk variants for CHD 2,3,12,13 in 4 Finnish prospective cohorts (n=24 124) with up to 19 years of follow-up. We set out to evaluate the genetic risk discrimination of CHD, acute coro-
Results

Background Characteristics of Study Cohorts
Characteristics of study cohorts are shown in Table 1 . In total, 24 124 subjects from FINRISK 1992 , FINRISK 1997 , FINRISK 2002 , and Health 2000 cohorts were included in the analysis. We observed 1093 CHD (5%), 1552 CVD (6%), and 731 ACS (3%) cases during the median follow-up time of 12 years (interquartile range 8.75-15.25 years).
Association Results
When tested individually, 5 loci were associated with all cardiovascular end points: rs6725887 (reported locus: WDR12), rs12526453 (PHACTR1), rs4977574 (CDKN2A/B, ANRIL), rs1746048 (CXCL12), and rs3825807 (ADAMTS7). In total, 13 loci were significantly associated with ≥1 of the end points.
( Table II in the online-only Data Supplement).
The GRS was associated with all cardiovascular end points ( Table 2) . Subjects in the highest 10% of 28-SNP GRS had 2.07-fold (95% confidence interval [CI], 1.68-2.56; P=9.8×10 −14 ) increased risk for CHD, when compared with the subjects in the middle 20%. When GRS was constructed by using only 13 SNPs that have been identified in the first phase of genome-wide studies, 1 the corresponding risk for 13-SNP GRS was 1.55 (95% CI, 1.26-1.91; P=4.7×10 −11 ).
When dividing the risk score into deciles, the highest GRS group was clearly distinguishable from the other groups, especially in CHD and CVD events ( Figure 1 and Figure I in the online-only Data Supplement). The deviation from the linear risk function was observed for the highest decile in CHD (additional HR over linear risk, 1.38; 95% CI, 1.12-1.72; P=0.003) and CVD (HR, 1.39; 95% CI, 1.15-1.67; P=0.0006), but not for ACS (HR, 1.16; 95% CI, 0.89-1.51; P=0.27). The nonlinearity does not seem to be driven by the weights in the GRS because similar nonlinear risk function was observed also for unweighted GRS ( Figure II in the online-only Data Supplement).
In FINRISK studies, family history of CVD was an independent risk factor for all events. Adjusting for the GRS slightly diminished the effects of family history: The estimated risk decreased from 1.46 (95% CI, 1.27-1.67) to 1.43 (95% CI, 1.25-1.64) for CHD, from 1.37 (95% CI, 1.22-1.53) to 1.35 (95% CI, 1.21-1.51) for CVD, and from 1.45 (95% CI, 1.24-1.71) to 1.43 (95% CI, 1.21-1.68) for ACS, for the models with and without the GRS, respectively. In comparison, the GRS effects (per SD of GRS) changed from 1.29 (95% CI, 1.20-1.38) to 1.28 (95% CI, 1.19-1.37) for CHD, from 1.19 (95% CI, 1.12-1.26) to 1.18 (95% CI, 1.12-1.25) for CVD, and from 1.30 (95% CI, 1.19-1.40) to 1.29 (95% CI, 1.19-1.40) for ACS, when family history was included into the model. 
Risk Discrimination and Reclassification
The model including traditional risk factors had the C-index of 0.849 for CHD, 0.835 for CVD, and 0.853 for ACS. Adding family history of CVD into the models improved C-index by 0.2% (P=0.03 for both CHD and CVD; Figure 2 ). The GRS further improved risk discrimination of all end points over and above traditional risk factors and family history by 0.3% to 0.5% (P=0.0002 for CHD; P=0.0004 for CVD; P=0.001 for ACS; Figure 2 ). There were 576 incident CHD cases in the combined 14-year follow-up of FINRISK 1992 and 1997. The family history of CVD did not improve the reclassification (net reclassification improvement [NRI]=0.1%; P=0.40). Adding the GRS into the model with traditional risk factors and family history resulted in overall NRI of 5% (P=0.01). We also observed a significant improvement in reclassification of individuals at the intermediate-risk category (clinical NRI=27%; P=1.1×10 −8 ). Overall, 52 CHD cases (27%) and 206 noncases (20%) in the intermediate-risk group were correctly reclassified, when the GRS was added into the model (Table 3) . We obtained essentially similar results for NRI in our sensitivity analysis with 2% higher category thresholds ( Table III in the online-only Data Supplement). Also, integrated discrimination improvement (value=0.007; P=4.2×10 -5 ) indicated statistically significant improvement in prediction, when genetic information was added to the model. Explained relative risk was 0.43 (SE=0.02) for the model without the GRS and 0.45 (SE=0.02) with the GRS. Calibration was good for all end points (Hosmer-Lemeshow test, 0.67>P>0.12).
We assessed the potential overfitting of the models by using the FINRISK 2002 as a training set and the joint FINRISK 1992 and 1997 data as a test data set. To keep the training and test data sets comparable, we excluded Health 2000 from the analysis because it lacks the information on family history. We estimated the effects for 2 models (with and without the GRS) in the training set data and used the estimated effect sizes from the training models to predict the 14-year absolute risk in the test data. The baseline hazard was estimated from the test data. This approach resulted in essentially similar results as a method, where effect sizes were estimated directly from the test data set ( Table IV in the online-only Data Supplement).
Traditional risk factor screening of 100 000 European individuals would classify 64 373 subjects into <10%, 18 223 into 10% to 20%, and 17 404 into ≥20% risk category (Figure 3 ). On the basis of the present guidelines, 10, 11 only individuals in the highest risk group are eligible for lipid medication. We also classified those subjects with baseline diabetes mellitus or lipid treatment directly to the high-risk category. Thus, subjects at the intermediate-risk category (10%-20%) were assumed not to receive statin treatment. Additional GRS screening of these subjects would reclassify 3475 subjects (19%) into the low-and 2144 (12%) into the high-risk category. Of the subjects reclassified into the high-risk category, 676 were expected to experience CHD event within 14 years. Assuming that statins reduce the risk by 20%, additional GRS screening could prevent 135 (676×0.2) CHD cases over 14 years. As a comparison, if statins would be randomly allocated for the same number of subjects (n=2144) in the intermediaterisk group, the expected number of prevented cases would be 54 (0.2×272, the expected number of cases). Thus, the GRS screening would prevent 2.5 times more events than the random allocation of statins to a comparable number of individuals predicted with intermediate risk in the absence of the GRS.
Discussion
We studied 4 prospective Finnish cohorts with genetic markers from 28 loci that have been associated with CHD or myocardial infarction in previous studies. 2, 3, 12, 13 The GRS based on these variants was strongly associated with cardiovascular events and improved risk discrimination for all end points (C-index change =0.3%-0.5%, all P values ≤0.001). GRS also improved risk reclassification of CHD in a joint FINRISK 1992 and FINRISK 1997 analyses Cox regression models were adjusted for sex, total cholesterol, high-density lipoprotein-cholesterol, body mass index, systolic blood pressure, antihypertensive treatment, smoking, and type 2 diabetes mellitus; age was used as the timescale.
ACS indicates acute coronary syndrome; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; GRS, genetic risk score; HR, hazard ratio; and N, number of individuals.
*Per SD of GRS. Our results allow us to draw the following conclusions, which may be of clinical interest when evaluating a healthy individual's risk for CHD. First, the GRS is associated with incident CHD with the risk >2-fold for an individual at the top 10% of GRS compared with an average subject. The risk for these individuals is higher than expected by a linear function (P=0.003) and may be underestimated by predictions based only on traditional risk factors. Second, the GRS improved risk prediction of CHD over and above the conventional risk factors and family history, when evaluated with either discrimination or reclassification measures. Improved risk classification led to more accurate risk categorization for individuals at intermediate-risk group, which means that a substantial proportion of CHD cases was reclassified upward and noncases downward in the risk scale (0%-5%, 5%-10%, 10%-20%, >20%). Because these risk categories have been developed to guide treatment decisions, improved risk reclassification may have public health benefits. To address this, we estimated the effect of reclassification in a population level. Our data suggest that targeted GRS screening in addition to traditional risk factor screening would prevent 1 additional CHD event during the period of 14 years for every 135 people (18 223/135) screened.
Strengths of our study include a large prospective data set and accurately defined event definitions, which have been drawn from the validated population registries. [14] [15] [16] [17] The main end point of our study was CHD (n=1093), rather than more heterogeneous CVD, which has been used in some other genetic risk prediction studies that have failed to show an incremental value of the GRS. 5, 7 However, our estimates are comparable with the recent study 6 that analyzed 742 CHD events and constructed the GRS with the comparable SNP set to our study. The authors observed improvements in reclassification (NRI=2.8%; P=0.031), but not in discrimination. The better statistical power attributable to the larger number of SNPs or CHD events in our study might partially explain why we observed improvement in both reclassification and discrimination. Also, genetic diversity is lower and the extent of linkage disequilibrium is higher in Finland than in other European populations, which might facilitate the study of genetic effects for complex diseases.
Our large population cohort is well suitable for clinical modeling, a concept that has been applied in 2 recent risk prediction studies. The Emerging Risk Factors Collaboration 9 studied the added use of lipid-markers in cardiovascular risk prediction. Additional screening based on lipoprotein(a) resulted in reclassification of 555 subjects from intermediate-to high-risk category and potential prevention of 17 CVD events over 10 years. The other study by the same collaboration 8 resulted in ≈30 prevented CVD cases over 10 years by additional CRP or fibrinogen screening. With restricted 10-year follow-up comparable with these studies, we estimate that additional genetic screening based on 28 SNPs could prevent 61 of all 6355 CHD cases over 10 years. Thus, the added use of 28-SNP GRS in risk prediction is superior compared with these other novel cardiovascular risk markers.
Our results should also be interpreted in the context of potential limitations of our study. Although our 28-SNP marker panel consists of lead SNPs from associated loci, we are only catching a fraction of all genetic risk variation for CHD. In our reclassification analyses, we combined 2 study cohorts and estimated 14-year CHD risk. However, established risk categories are usually applied for a 10-year time frame and may not be directly applicable to our extended follow-up period. We, however, have addressed this issue by performing a sensitivity analysis with 2% higher risk thresholds. Also, we assumed that all participants eligible for statin treatment would receive them, which might overestimate the benefits of 2-stage risk screening. In practice, compliance to treatment might not be complete. Finally, this study was conducted using a Finnish population sample, and the generalizability of these results to other populations, especially to those of non-European ethnicity, needs to be confirmed.
In conclusion, GRS improves CHD risk discrimination and reclassification over and above traditional risk factors and family history. Additional GRS screening of individuals at intermediate cardiovascular risk could help to prevent future cases through more accurate statin allocation. The clinical, economical, and practical use of the genetic testing needs to be further tested.
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